

Stability Indicating RP-HPLC Method Development and Validation for Determination of Ondansetron in Bulk and Pharmaceutical Dosage Form

Rahul Shirole^{1*}, Tabrej Mujawar², Vilas Badgujar³, Tanvir Ahmad Shaikh⁴, Ansari Yaasir Ahmed⁵, Hemant Deore¹, Surti Sehjad⁶, Shaikh Altaf Ahamad⁷, Qazi Wasil⁸, Jain Nilesa⁹, Aatif Shaikh¹⁰, Makrani Shaharukh¹¹, Bagnawar Asha Maruti¹²

1. Dept. of Pharmacology, DCS's A. R. A. College of Pharmacy, Nagaon, Dhule: 424005, Maharashtra, India.
2. Dept. of Pharmacology, Gangamai College of Pharmacy, Dhule: 424005, Maharashtra, India.
3. Dept. of Pharmaceutical Chemistry, DCS's A. R. A. College of Pharmacy, Nagaon, Dhule: 424005, Maharashtra, India.
4. Dept. of Pharmaceutics, DCS's A. R. A. College of Pharmacy, Nagaon, Dhule: 424005, Maharashtra, India.
5. Dept of Quality Assurance, Ali Allana College of Pharmacy, Akkalkuwa Dist- Nandurbar: 425415, Maharashtra, India.
6. Dept. of Pharmaceutical Analysis, School of Pharmacy, Parul University, Vadodara: 391760, Gujarat, India.
7. Dept. of Pharmacognosy, P.G.College of Pharmaceutical Sciences & Research, Chaupale, TalDist: Nandurbar: 425411, M.S., India.
8. Dept. of Pharm.Chemistry, Jamia College of Pharmacy, Akkalkuwa, Dist-Nandurbar: 425415, M.S., India.
9. Dept. of Pharmacology, DCS's Institute of Pharmacy, Deopur, Dhule: 424002, Maharashtra, India.
10. Dept. of Pharmaceutics, Anjuman-I-Islam's Kalsekar Technical Campus, School of Pharmacy, New Panvel, Navi Mumbai: 410206, M.S., India.
11. Dept of Quality Assurance, Ali Allana College of Pharmacy, Akkalkuwa Dist- Nandurbar: 425415, Maharashtra, India.
12. Dept of Pharmaceutical Chemistry, Shreeyash Institute of Pharmacy, Chh.Sambhajinagar-431102, Maharashtra, India.

Corresponding Author: Dr. Rahul Lotan Shirole, Dept. of Pharmacology, DCS's A. R. A. College of Pharmacy, Nagaon, Dhule: 424005, Maharashtra, India. E mail: rahulshirole@gmail.com

ABSTRACT: A new Stability indicating HPLC method has been developed and validated with different parameters for Ondansetron. The chromatographic conditions were optimized using a mobile phase of Acetonitrile: Water (0.1 % OPA) (25:75) and drug flows at a rate of 1 ml/min. Column (C18) of 4.6 x 250 mm dimension was used as a stationary phase, particle size capacity of column was 5µm. The detection was carried out at 314 nm. The method was validated according to ICH guidelines with different parameters. The response was found to be linear in concentration range of 4-20 µgm/ml for Ondansetron. The accuracy was carried out at 80%, 100%, and 120%. The % recovery was found to be average 100.50%. The assay of marketed formulation was carried out and % purity of Formulation was 99.51%. The method was linear, simple, precise and accurate and therefore suitable for routine analysis of drugs in tablet form.

KEYWORDS: HPLC, Ondansetron, Development, Validation, Forced degradation.

1. INTRODUCTION

HPLC has 2 types i.e. NP-HPLC and RP-HPLC. In this Chromatographic study, we have selected RP-HPLC. In RP-HPLC method, mobile phase is polar and stationary phase is non-polar. Chromatographic separation in HPLC is a result of specific interaction of drug with mobile and stationary phase. Mobile phase runs the solution of drug through the column. Column acts as stationary phase. HPLC contains different parts from Mobile phase reservoir, Degasser, column to the detector for analyzing different samples. Current chromatographic separation involves the study of ondansetron. HPLC method has been developed and validated for the determination of Ondansetron in bulk and dosage form. Ondansetron is an anti-emetic drug. Ondansetron is administered to prevent Nausea and emesis i.e. vomiting generally in Radiation therapy, chemotherapy etc.




Figure 1: Structure of Ondansetron

2. MATERIALS AND METHODS

Reagents and Chemicals:

Ondansetron reference standard was supplied by J.B Chemicals, Ankleshwar, India. Pharmaceutical dosage form (Doran-D Injection) was obtained commercially. Acetonitrile and O-Phosphoric acid as HPLC grade were used as solvents.

Methodology

Preparation of Mobile phase

A mixture of Acetonitrile and Water (0.1% o-phosphoric acid in water) in the ratio of 25:75 was prepared (filtered and degassed).

Preparation of standard solution

Standard stock solution of Ondansetron was prepared by dissolving 4 mg of Ondansetron in 10 ml MeOH, to get solution containing 400 µg/ml Ondansetron (STOCK- I). Then, this stock solution is diluted to get solutions containing 4-20 µg/ml Ondansetron.

Formulation solution Preparation:-

4 ml Injection (containing 4 mg Ondansetron) was transferred into 10 ml volumetric flask and mixed in methanol and then diluted up to the mark. Now, the solution contains 400 µg/ml Ondansetron (Stock Solution-II).

Assay:-

For assay, take 0.3ml from Stock solution-II and makeup volume upto 10 ml with mobile phase to get 12 µg/ml Ondansetron.

Forced Degradation Sample Preparation:

This Study was carried out to check the effective separation of Ondansetron and their degradation product. Forced degradation study was performed to evaluate the stability indicating properties of the method. Forced degradation study was carried out by treating sample with Acid, alkali, Hydrogen peroxide (oxidative degradation), Neutral (Water). These are given below--

1) Acidic Degradation

0.2 ml sample was taken from stock solution-I and transferred in 10 ml volumetric flask. To this, 5 ml 1 N Hydrochloric acid (HCL) was added, solution was made up to the mark with mobile phase and solution was heated at 60° C for 30 minutes. After 30 minutes flask were removed and cooled to room temperature. The Chromatogram was recorded for this solution.

2) Alkaline degradation

Sample (0.2 ml) was taken from stock solution-I and transferred in 10 ml volumetric flask. To this, 5 ml 1 N Sodium hydroxide (NaOH) was added, solution was made up to the mark with mobile phase and solution was heated at 60° C for 30 minutes. After 30 minutes flask were removed and cooled to room temperature. The Chromatogram was recorded for this solution.

3) Oxidative degradation

Sample of 0.2 ml was taken from stock solution-I and transferred in 10 ml volumetric flask. To this, 5 ml 10 % Hydrogen peroxide (H₂O₂) was added, solution was made up to the mark with mobile phase and solution was heated at 60° C for 30 minutes. After 30 minutes flask were removed and cooled to room temperature. The Chromatogram was recorded for this solution.

4) Hydrolysis

0.2 ml sample was taken from stock solution-I and transferred in 10 ml volumetric flask. To this, 5 ml water was added, solution was made up to the mark with mobile phase and solution was heated at 60° C for 30 minutes. After 30 minutes flask were removed and cooled to room temperature. The Chromatogram was recorded for this solution.

Method Validation

Method validation was done, to show that the method is suitable for assay and stability studies of Ondansetron. The method validation was carried out as per ICH guidelines for precision, linearity, accuracy, Robustness, LOD and LOQ in analytical solution (ICH 1996, Q2 (R1) ICH, 2005).

i) System Suitability Study

20 µl of standard preparations in five replicates were injected. The chromatogram and peak responses were measured for Ondansetron. System suitability of the method was evaluated in terms of R_t, peak area, theoretical plate, tailing factor and resolution.

ii) Linearity

Linearity of Ondansetron was determined by preparing standard solution at five concentrations in the range of 4-20 µg/ml for Ondansetron from the stock solution. 20 µl of each solution was injected into the HPLC system and the peak area of chromatogram was noted. The standard deviation and % relative standard deviation of peak areas were calculated. Mean AUC was plotted against concentration to obtain the calibration curve. Correlation coefficients were calculated from calibration curve.

iii) Accuracy (Recovery Study)

Recovery experiments were carried out to study the reliability and suitability of standard method at three different levels (80%, 100% & 120%). These samples of Ondansetron were analysed and recovery was calculated.

iv) Precision

a) Intraday Precision

Three samples containing known amount of Ondansetron (8, 12 and 16 µg/ml) were put into HPLC system and analysed as per test method and % RSD for Ondansetron were calculated.

v) Robustness

Robustness of the method was studied by varying the chromatographic conditions like change in Mobile Phase Composition, Flow rate and Wavelength. The sample solutions were applied onto the column and the response was determined.

Results and Discussion**Optimization of Chromatographic condition (Method Development):**

Individual drugs and their mixture were taken in various combination of mobile phase for chromatographic study. Proper selection of the method depends upon the nature of the sample (ionic/ionisable/neutral molecule, its molecular weight and solubility). Here, the RP-HPLC method was selected for initial separation because of its simplicity and suitability. Various mobile phases such as acetonitrile and water, acetonitrile and buffer, were tried. Finally, Acetonitrile and Water (0.1% ortho-phosphoric acid in water) were used as mobile phase in the ratio of 25:75 for further chromatographic study. The results of these trials are reported in Table 1.

Table 1: Trials & Optimization of Chromatographic condition

Trial No	Chromatographic condition	Remarks
1	Mobile phase- Acetonitrile: Water (20:80) (0.1 % OPA in water) Flow rate- 0.7 ml/min, λ_{\max} – 314 nm	Not Sharp Peak Rejected
2	Mobile phase- MeOH: Water (30:70) (0.05 % OPA in water) Flow rate- 0.7 ml/min, λ_{\max} – 314 nm	Not Sharp Peak Rejected
3	Mobile phase- Acetonitrile: Water (25:75) (0.1 % OPA in water) Flow rate- 1 ml/min, λ_{\max} – 314 nm	Sharp Peak Selected




Figure 2: Optimized Graph of Ondansetron

Optimised chromatographic condition:

HPLC : AGILENT (1100) Gradient System with manual injector

Detector : UV

Column : C18 (4.6 x 250 mm id)

Particle size packing : 5 μ m

Mobile Phase : Acetonitrile: Water (0.1 % OPA) (25:75)

Detection wavelength: 314 nm

Flow rate : 1 ml/min

Temperature : Ambient

Sample Size : 20 μ l**HPLC Method Validation****i) System suitability test (Repeatability)**

System Suitability Tests were carried out on standard solutions containing Ondansetron. System suitability parameters are obtained with 20 μ l injection volume. Retention time (mean) was found to be 6.536 for Ondansetron respectively. Theoretical plates, tailing factor (peak asymmetry) and resolution were observed. It is summarised in Table 2.

Table 2: System suitability test (Repeatability)

Sr. No	RT[min]	Area[mV*s]	TP	TF	Resolution
1	6.536	2554.60	6440	0.41	15.21
2	6.536	2535.63	6448	0.41	15.21
Mean	6.536	2545.12	6444	0.41	15.21




Figure 3: Chromatogram of System suitability Test




Figure 4: Chromatogram of System suitability Test

ii) Linearity

The concentrations ranging from 4-20 $\mu\text{g}/\text{ml}$ of Ondansetron were injected and peaks were recorded. In these concentrations baseline were obtained for the drug. The correlation coefficient (r^2) value was 0.999 for the drug i.e. Ondansetron. The %RSD for these concentrations was 0.72, 0.18, 0.26, 0.21 and 0.29 respectively. The graph was plotted as a concentration of drug versus peak area is depicted in figure 5.




Figure 5: Standard calibration curve of Ondansetron

iii) Precision

Intraday Precision

Table 3- displayed the study of Intraday Precision of Ondansetron. For this, Ondansetron is used in a concentration of 8-16 $\mu\text{g}/\text{ml}$. The % of amount found for these concentrations were 101.25, 99.33 and 101.25 respectively. The %RSD for these concentrations was 0.89, 0.44, and 0.39.

Table 3: Intraday Precision

Sr No.	Conc.	Area I	Area II	Mean	Amt Found	% Amt Found	SD	%RSD
1	8	380.39	375.23	377.81	8.10	101.25	100.45	0.89
2	12	541.85	545.21	545.21	11.92	99.33	2.38	0.44
3	16	731.18	735.26	733.22	16.20	101.25	2.88	0.39

iv) Accuracy

Table 4- displayed the Accuracy (% Recovery) study of Ondansetron. For this, Ondansetron is used in a concentration of 80%, 100% and 120%. The mean of % amount recovered of these concentrations was 100.90, 101.56 and 100.58 respectively.

Table 4: Accuracy (% Recovery study)

Sample Conc.	µgm/ml	Amt added	Area	Amt found	Amt rcvd	% rcvd	Mean	SD	%RSD
80%	8	6.4	655.65	14.43	6.43	100.57	100.90	0.46	0.46
	8	6.4	657.45	14.47	6.47	101.22			
100%	8	10	730.58	16.14	8.14	101.80	101.56	0.34	0.33
	8	10	728.89	16.10	8.10	101.32			
120%	8	9.6	799.7	17.71	9.71	101.24	100.58	0.93	0.93
	8	9.6	795.14	17.59	9.59	99.92			

v) Robustness**Robustness (Ondansetron)**

Table 5- displayed the Robustness study of Ondansetron. Robustness studies of System were performed by changing the flow rate, M.P concentration and wavelength. The mean found were 606.81 and 496.87 for the flow rate of 0.6 ml/min and 0.8 ml/min respectively. The %RSD found were 0.80 and 0.90 for the flow rate of 0.6 ml/min and 0.8 ml/min respectively. The mean found were 540.9 and 540.76 for Mobile Phase Concentration (74:26) and Mobile Phase Concentration (76:24) respectively. The %RSD found were 0.35 and 0.55 for Mobile Phase Concentration (74:26) and Mobile Phase Concentration (76:24) respectively. The mean found were 562.60 and 523.06 for Wavelength (232 nm) and Wavelength (234 nm) respectively. The %RSD found were 0.66 and 0.35 for Wavelength (232 nm) and Wavelength (234 nm) respectively. This study shows that system is robust and withstand by changing different aspects of system.

Table 5: Robustness study (Ondansetron)

Conc.(µgm/ml)	Area	Mean	SD	%RSD
Change in Flow rate (0.9 ml/min)				
12	603.39	606.81	4.84	0.80
12	610.23			
Change in Flow rate (1.1 ml/min)				
12	493.72	496.87	4.45	0.90
12	500.01			
Change in Mobile Phase Concentration (26:74)				
12	542.27	540.9	1.90	0.35
12	539.58			
Change in Mobile Phase Concentration (24:76)				
12	538.64	540.76	2.99	0.55
12	542.87			
Change in Wavelength (313 nm)				
12	560.01	562.60	3.69	0.66
12	565.23			
Change in Wavelength (315 nm)				
12	521.76	523.06	1.84	0.35
12	524.36			

Assay of Marketed formulation:

Marketed formulation (Doran-D Injection) of Ondansetron was analysed and % purity was determined. The mean of % assay was found to be 99.51 for Ondansetron in injection. The result of assay is shown in Table 6 and chromatograms are shown in figure 7.




Figure 7: Chromatogram of Assay
Table 6: Assay of Marketed formulation

Conc. μgm/ml	Area I	Area II	Mean	Amt Found	% Found	Amt Found	SD	%RSD
Ondansetron								
12.00	543.15	549.23	546.19	11.94	99.51		0.07	0.07

Forced Degradation Study

Standard sample of Ondansetron was undergone acidic, alkaline, Oxidative and Hydrolytic degradation. The sample shows 15%, 14%, 17% and 0.1% degradation in acidic, alkaline, Oxidative and Hydrolysis conditions respectively. The degradation was under acceptance criteria. It shows stability indicating properties of the method. The chromatograms of sample are shown in Figure 8 and 9.




Figure 8: Acidic degradation (0.1 N HCL)




Figure 9: Alkaline degradation (0.1 N NaOH)

CONCLUSION

The aim of current chromatographic study was to develop Stability indicating HPLC method for the estimation of Ondansetron in bulk and dosage form. Hence, Stability indicating RP-HPLC method has been developed and validated for LOD and LOQ. Forced degradation study was also performed under four different stress conditions. From the chromatographic study, we concluded that developed method is more linear, accurate, precise, reliable and reproducible for routine analysis of Ondansetron in bulk and Pharmaceutical dosage form. So one can perform validation and forced degradation study.

ACKNOWLEDGEMENT

Authors are thankful to the Chairman and Management, Principals and Teaching & Non-Teaching Staff of the respective institute, for their kind Support and motivation during research work.

REFERENCES

1. A. LakshmanaRao, G. Akanksha, G. Neelima, G. Sneha, G.V. Pavan Kumar, G. Lavanya. Stability Indicating RP-HPLC Method Development and Validation for the Estimation of Ondansetron in Bulk and their Pharmaceutical Dosage Form. International Journal of Research in AYUSH and Pharmaceutical Sciences, 2021;5(7):557-563. <https://doi.org/10.47070/ijraps.v5i7.118>
2. United State Pharmacopoeia -30, National Formulary - 25, 2007, By Authority of the United State Pharmacopoeial Convention, Inc. Prepared by the Council of Experts and Published the Board of Trustees: 1456, 2569.
3. SN Meyyanathan, D NagasamyVenkatesh, N Krishnaveni, B Babu, MR Jeyaprakash, Rajnikanth B Raja. A RP-HPLC method for simultaneous estimation of Ondansetron and Ranitidine in Pharmaceutical formulation. International journal of Health and Allied Science.2012; 1(2):129-132.
4. Vaibhav R. Mandale, Subhash S. Palekar, Monali V. Patel, Niyati A. Borkar, Avinash R. Tekde, Archana M. Karnik. Development and Validation of RP-HPLC method for the simultaneous estimation of Ranitidine and Ondansetron in Pharmaceutical Formulations. World journal of Pharmaceutical Research.2015; 4(1):1872-1881.
5. Nayeem Khan, Aejaz Ahmed, Majaz Qazi, Yaasir Ahmed Ansari, Afsar Shaikh, Ayyaj A. Badgire, Mohd Salman, Noosrat Jahan Khan. Development and Validation of Stability-Indicating RP-Hplc Method for Simultaneous Determination of Canagliflozin and Metformin in Fixed-Dose Combination. Journal of Research in Pharmacy. 2023; 27(3): 1234-1241.
6. Vaibhav R. Mandale, Dr.Subhash S. Palekar, Dr.PrakashT.Sangale, Dr.TaukeerKadu, Dr.Atul S. Sayare, Archana M. Karnik. Development and Validation of UV Spectrophotometric method for the simultaneous estimation of Ranitidine and Ondansetron in bulk and Pharmaceutical Formulation. World journal of Pharmaceutical Research.2015; 4(2):1093-1101.
7. Ahmed AY, Shoeb Q, Rumana U, Patel A, Tajkhan PV, Shaharukh M. Development and validation of stability-indicating reverse phase-high performance liquid chromatography method for simultaneous determination of atenolol and nifedipine in bulk and tablet dosage form. International Journal of Pharmaceutical Quality Assurance. 2020;11(2):219-223. <https://doi.org/10.25258/ijpqa.11.2.4>
8. Patel P.J, Shah D.A, Mehta F.A and Chhalotiya U.K. Development of liquid chromatographic method for estimation of Ondansetron and Ranitidine in combined dosage form. Austin chromatography. 2015; 2(2):1033.
9. Priyanka K, K. Vennela, M. Monika Reddy. A new RP-HPLC method development and Validation for simultaneous estimation of Ranitidine and Ondansetron in its pure and Pharmaceutical dosage form. IJIPSR.2014; 2(12):2971-2979.
10. CH. Priyanka, T. Lalitha, B. MadhaviLatha, Dr. D. Satyavati, V. Abhishiktha. Analytical method development and Validation for simultaneous estimation of Ranitidine and Ondansetron in its pure and Tablet dosage form by RP-HPLC. Journal of Pharma Research. 2018; 7(8):182-185.

11. PravinShende, EktaAtrey and Gaud RS. RP-HPLC method development and Validation for simultaneous estimation of Ondansetron HCL and Complexed Famotidine in Bulk and Dosage form. *Journal of analytical and Pharmaceutical Research*.2017; 5(2): 00138.
12. Rao A.L. Simultaneous determination of Ranitidine HCL and Ondansetron HCL in bulk drug and Tablet dosage form by UV spectrophotometry. *Journal of pharmaceutical Research*. 2017; 1(5):000128.
13. I. Singhvi and S. Pillai. Spectrophotometric simultaneous estimation of Ranitidine HCL and Ondansetron HCL from Tablet formulation, *Indian journal of Pharmaceutical Science*.2007; 69(4):601-604.
14. P.B. Raval, ManishaPuranik, S J Wadher and P G Yeole 2008. HPTLC determination of Ondansetron in combination with Omeprazole or Rabeparazole in solid Dosage form. *Indian Journal of Pharm. Science*: 386-390.
15. T. Santhosh Kumar, B. KalyanKumar,A. Shravan Kumar, M.Murali Mohan, S.S Nanda, P.VenkateshwarRao. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Esomeprazole and Domperidone in Pharmaceutical Dosage Form. *Journal of Pharmacy Research*.2011; 4(11):4097-4099.
16. Ansari Yaasir Ahmed, Zakariya Patel, Rahil Khan, Huzaifa Patel, Syed Abdul Azeem. HPLC method Validation for the estimation of Aspirin in Bulk and Tablet dosage form as per USP. *International Journal of Research in Advent Technology*. 2019; 7(4S):69-73.
17. Arshiya Fatima, B. Sreedevi, Ramya Sri S. and M. A. Haneef. Rp-Hplc Method Development and Validation for Simultaneous Estimation of Ranitidine Hydrochloride and Ondansetron Hydrochloride in Pure and Tablet. *World Journal of Pharmaceutical Research*. 2016; 5(12):471-480.
18. R N Varade, P Tak and H Mishra. Development and Validation of Rapid RPHPLC Method for Estimation of Ondansetron in the Tablet Dosage Form. *Int J Pharm Biol Sci*. (2021) 11 (1): 141-146. DOI: <https://doi.org/10.21276/ijpbs.2021.11.1.19>